Fig. 6

High OSBPL3 Expression Predicts Poorer Response to Immunotherapy. (A) Z-scores of MHC, EC, CP, and SC in the top 5 samples with low and high OSBPL3 expression. (B) Density plot showing the distribution of Immunotherapy Prediction Score (IPS) values, derived from the integration of MHC, EC, CP, and SC scores, in pancreatic cancer samples with high and low OSBPL3 expression. (C) MHC, EC, and CP values in high- and low-expression OSBPL3 groups. Non-parametric tests were performed, with * indicating P < 0.05, ** indicating P < 0.01, and *** indicating P < 0.001. (D) Distribution of immune-positive cells (scAB + cells) and other cells in pancreatic cancer ductal cell subpopulations with high and low OSBPL3 expression, predicted by the scAB algorithm. (E) Proportion of CR/PR and SD/PD response groups in different OSBPL3 expression groups of mUC patients from the IMvigor210 dataset following immunotherapy. Expression of OSBPL3 in different immune therapy response groups of mUC patients from the IMvigor210 dataset. (F) Correlation between OSBPL3 expression and immune therapy response in the lung cancer immunotherapy dataset GSE135222. (G) Survival analysis of OSBPL3 expression in lung cancer patients after immunotherapy